Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma; Advanced Solid Tumor; Non-small Cell Lung Cancer; Metastatic Melanoma Interventions: Drug: BGB-10188; Drug: Zanubrutinib; Drug: Tislelizumab Sponsor: BeiGene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Leukemia | Lymphoma | Melanoma | Research | Skin Cancer | Study